Detail akcie Genflow Bio Rg online

Business Summary: Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product line includes GF-1002, GF-3001 and GF-4001. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-4001 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-3001 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Genflow Biosciences PLC revenues was not reported. Net loss decreased 16% to L524K. Lower net loss reflects Other Operating Income increase from L194K to L792K (income), Total administrative expenses - Balanc decrease of 16% to L176K (expense), Directors fees decrease of 2% to L184K (expense).